← Leaderboards
Reina C Villareal
Michael E Debakey Va Medical Center
$2,493,869
Attributed
$2,493,869
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $387.7K · FY2005–25$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,493,869 · 3
VA$0 · 2
By mechanism
R01$1,905,968 · 1
R21$363,651 · 1
R03$224,250 · 1
I01$0 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Bone Density”
- Richard A Gibbs · Baylor College Of Medicine$49,965,365
- Steven R Cummings · University Of California San Francisco$45,557,505
- Peter J. Snyder · University Of Pennsylvania$37,887,894
- Douglas P. Kiel · Hebrew Rehabilitation Center For Aged$31,628,442
- Eric S. Orwoll · Oregon Health And Science University$27,305,691
- Hong-Wen Deng · Father Flanagan'S Boys'Home$24,036,296
Research focus
Bone DensityBone TurnoverProductionAndrogensAromataseBone MetabolismEstradiolReportingRandomizedPlacebosTestosteroneHypogonadismMaleBone QualityBoneEstrogensElderly ManObesityBone LossResponseFractureQuality Of LifeEnzymesOsteoporosis
Grant awards (20)
Testosterone Therapy and Bone Quality in Men with Diabetes and Hypogonadism$0
I01 · FY2025 · VA · contact PI
Testosterone Therapy and Bone Quality in Men with Diabetes and Hypogonadism$0
I01 · FY2024 · VA · contact PI
Testosterone Therapy and Bone Quality in Men with Diabetes and Hypogonadism$0
I01 · FY2023 · VA · contact PI
Aromatase Inhibitors and Weight Loss in Severely Obese Men with Hypogonadism$373,822
R01 · FY2022 · HD · contact PI
Testosterone Therapy and Bone Quality in Men with Diabetes and Hypogonadism$0
I01 · FY2022 · VA · contact PI
Aromatase Inhibitors and Weight Loss in Severely Obese Men with Hypogonadism$373,822
R01 · FY2021 · HD · contact PI
Testosterone Therapy and Bone Quality in Men with Diabetes and Hypogonadism$0
I01 · FY2020 · VA · contact PI
Testosterone Therapy and Bone Quality in Men with Diabetes and Hypogonadism$0
I01 · FY2020 · VA · contact PI
Aromatase Inhibitors and Weight Loss in Severely Obese Men with Hypogonadism$383,504
R01 · FY2019 · HD · contact PI
Aromatase Inhibitors and Weight Loss in Severely Obese Men with Hypogonadism$387,739
R01 · FY2018 · HD · contact PI
Aromatase Inhibitors and Weight Loss in Severely Obese Men with Hypogonadism$387,081
R01 · FY2017 · HD · contact PI
CYP19A1 gene and Pharmacogenetics of Response$0
I01 · FY2014 · VA · contact PI
CYP19A1 gene and Pharmacogenetics of Response$0
I01 · FY2013 · VA · contact PI
CYP19A1 gene and Pharmacogenetics of Response$0
I01 · FY2012 · VA · contact PI
AROMATASE INHIBITORS: SKELETAL EFFECTS AND THE ROLE OF CYP19 GENE POLYMORPHISMS$162,351
R21 · FY2007 · AR · contact PI
AROMATASE INHIBITORS: SKELETAL EFFECTS AND THE ROLE OF CYP19 GENE POLYMORPHISMS$201,300
R21 · FY2006 · AR · contact PI
CYP gene polymorphism and estrogen status in the elderly$74,750
R03 · FY2005 · AR
CYP gene polymorphism and estrogen status in the elderly$74,750
R03 · FY2004 · AR
CYP gene polymorphism and estrogen status in the elderly$74,749
R03 · FY2003 · AR
CYP gene polymorphism and estrogen status in the elderly$1
R03 · FY2003 · AR